Journal
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 23, Issue 5, Pages 597-606Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.beem.2009.05.006
Keywords
thyroid hyperfunction; TSH-induced; TSH-secreting pituitary adenomas (TSHomas); resistance to thyroid hormones; thyrotropin (thyroid-stimulating hormone, TSH); pituitary glycoprotein hormone; alpha-subunit (alpha-GSU); somatostatin analogues; (octreotide, lanreotide)
Categories
Funding
- Ricerca Corrente Funds of Fondazione Policlinico IRCCS (Milan, Italy)
- Istituto Auxologico Italiano IRCCS (Milan, Italy)
Ask authors/readers for more resources
Thyrotropin-secreting pituitary adenomas (TSHomas) are a rare cause of hyperthyroidism and account for less than 2% of all pituitary adenomas. In the last years, the diagnosis has been facilitated by the routine use of ultra-sensitive TSH immunometric assays. Failure to recognise the presence of a TSHoma may result in dramatic consequences, such as improper thyroid ablation that may cause the pituitary tumour volume to further expand. The diagnosis mainly rests on dynamic testing, such as T3 suppression tests and TRH, which are useful in differentiating TSHomas from the syndromes of thyroid hormone resistance. The first therapeutical approach to TSHomas is the pituitary neurosurgery. The medical treatment of TSHomas mainly rests on the administration of somatostatin analogues, such as octreotide and lanreotide, which are effective in reducing TSH secretion in more than 90% of patients with consequent normalisation of FT4 and FT3 levels and restoration of the euthyroid state. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available